KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.

R Liu, J Zhao, R Zhang, B Liu, Y Liu, S Li, Y Chen, H Yang, Z Liu, Z Li, Y Qin, M Huang, Y Ba, H Zhang, Y Qu, Y Du, T Deng, M Yang, X Hou, C Liu, F Ning, Y P Liu, X Wu, Y Xie, Y An, K Zou, L She, J Xu

Ann Oncol 37(6) 777-786

PMID41571045
PMCID-
DOI10.1016/j.annonc.2026.01.006
发表日期2026-01-22
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Gastric cancer after progression on trastuzumab treatment remains an unmet therapeutic challenge and is associated with suboptimal progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: This multicenter, randomized, double-blind, phase III trial was conducted at 51 hospital sites in China. Patients with HER2-positive gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma whose previous therapy containing trastuzumab had failed were randomized (1 : 1) to receive anbenitamab 30 mg/kg or placebo every 3 weeks, in combination with chemotherapy (paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on day 1 of a 21-day cycle, or irinotecan 125 mg/m2 on day 1 and 8 of a 21-day cycle), stratified by combined chemotherapy [taxane (paclitaxel or docetaxel) or irinotecan], HER2 expression [immunohistochemistry (IHC) 3+ or IHC 2+/FISH+], and previous lines of therapy (1 or ≥2). Primary endpoints were independent review committee-assessed PFS and OS in the intention-to-treat population. This interim analysis was planned when ∼120 PFS events were observed. RESULTS: A total of 188 patients were enrolled and assigned to receive anbenitamab plus chemotherapy (anbenitamab group, n = 95) or chemotherapy alone (control group, n = 93). At the prespecified interim analysis, anbenitamab plus chemotherapy significantly improved PFS [median 7.1 months, 95% confidence interval (CI) 5.5-10.3 months versus 2.7 months, 95% CI 1.5-3.0 months; hazard ratio (HR), 0.25, 95% CI 0.17-0.39, P < 0.0001] and OS (median 19.6 months, 95% CI 15.0 months to not evaluable versus 11.5 months, 95% CI 6.5-14.4 months; HR 0.29, 95% CI 0.17-0.50, P < 0.0001) compared with chemotherapy alone. Grade 3 or higher treatment-related adverse events occurred in 56 (60%) of 94 patients who received anbenitamab plus chemotherapy and 42 (45%) of 93 patients who received chemotherapy alone, with neutropenia (30% versus 22%) and leukopenia (21% versus 25%) being most common. Treatment-related deaths were reported in 0 and 5 patients in the anbenitamab and control groups, respectively. CONCLUSIONS: Compared with chemotherapy alone, anbenitamab plus chemotherapy demonstrated clinically meaningful superior PFS and OS in patients with HER2-positive GC/GEJ adenocarcinoma whose previous therapy containing trastuzumab had failed. These findings warrant confirmation in the final analysis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。